Intracoronary lithotripsy for calcific neoatherosclerotic in-stent restenosis: a case report

Helena Tizón-Marcos1,2,3, Iris Rodríguez-Costoya1,2,3, Cristina Tevar1,2

  • 1Cardiology Department, Hospital del Mar, Passeig Marítim 25-29, 08003 Barcelona, Spain.

Insights

Intravascular lithotripsy successfully treated calcific neoatherosclerosis causing in-stent restenosis. Balloon rupture occurred but did not harm the artery, highlighting a new complication of this promising treatment.

Area of Science:

  • Cardiovascular Interventions
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • In-stent restenosis (ISR) poses a significant challenge in percutaneous coronary interventions.
  • Calcific neoatherosclerosis is a complex etiology underlying difficult ISR cases.
  • Management of severely calcified lesions requires advanced treatment strategies.

Observation:

  • A patient with prior percutaneous coronary intervention (PCI) presented with non-ST-elevation myocardial infarction.
  • Intracoronary imaging revealed ISR attributed to calcific neoatherosclerosis.
  • Intravascular lithotripsy (IVL) was employed to fracture the calcified plaque.

Findings:

  • IVL effectively fractured the calcified neoatherosclerotic plaque in the left anterior descending coronary artery.
  • A balloon rupture occurred during the IVL procedure.
  • Despite the balloon rupture, no arterial damage was observed.

Implications:

  • Intravascular lithotripsy shows promise for treating extremely calcified lesions, including calcific neoatherosclerosis in ISR.
  • Balloon rupture is an identified complication of IVL, necessitating further investigation and management strategies.
  • This case expands the understanding of IVL procedural risks and benefits in complex coronary interventions.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...